Details of the Drug

General Information of Drug (ID: DMRINBJ)

Drug Name

TAK-169

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Recombinant protein

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclic ADP-ribose hydrolase 1 (CD38)	TTPURFN	CD38_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

02 Neoplasm

Disease Class

ICD-11: 2C82 Prostate cancer

The Studied Tissue

Bone marrow

The Studied Disease

Multiple myeloma [ICD-11:2C82]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cyclic ADP-ribose hydrolase 1 (CD38)	DTT	CD38	8.33E-02	0.22	0.69

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04017130) A Study of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Molecular Templates.